Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern.

Autor:	Favorskaya IA; Medical Microbiology Department, Federal State Budget Institution 'National Research Center for Epidemiology and Microbiology Named after Honorary Academician N.F. Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Shcheblyakov DV; Department of Genetics and Molecular Biology of Bacteria, Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N.F. Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Esmagambetov IB; Department of Genetics and Molecular Biology of Bacteria, Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N.F. Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Dolzhikova IV; Department of the National Virus Collection, Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N.F. Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Alekseeva IA; Department of Genetics and Molecular Biology of Bacteria, Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N.F. Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Korobkova AI; Department of Genetics and Molecular Biology of Bacteria, Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N.F. Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Voronina DV; Department of Genetics and Molecular Biology of Bacteria, Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N.F. Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Ryabova EI; Department of Genetics and Molecular Biology of Bacteria, Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N.F. Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Derkaev AA; Department of Genetics and Molecular Biology of Bacteria, Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N.F. Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Kovyrshina AV; Department of the National Virus Collection, Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N.F. Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Iliukhina AA; Department of the National Virus Collection, Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N.F. Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Botikov AG; Department of the National Virus Collection, Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N.F. Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Voronina OL; Department of Genetics and Molecular Biology of Bacteria, Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N.F. Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Egorova DA; Department of Genetics and Molecular Biology of Bacteria, Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N.F. Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Zubkova OV; Department of Genetics and Molecular Biology of Bacteria, Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N.F. Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Ryzhova NN; Department of Genetics and Molecular Biology of Bacteria, Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N.F. Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Aksenova EI; Department of Genetics and Molecular Biology of Bacteria, Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N.F. Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Kunda MS; Department of Genetics and Molecular Biology of Bacteria, Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N.F. Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Logunov DY; Medical Microbiology Department, Federal State Budget Institution 'National Research Center for Epidemiology and Microbiology Named after Honorary Academician N.F. Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Naroditsky BS; Department of Genetics and Molecular Biology of Bacteria, Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N.F. Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Gintsburg AL; Department of Genetics and Molecular Biology of Bacteria, Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N.F. Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2022 Feb 24; Vol. 13, pp. 822159. Date of Electronic Publication: 2022 Feb 24 (Print Publication: 2022).
DOI:	10.3389/fimmu.2022.822159
Abstrakt:	Virus-neutralizing antibodies are one of the few treatment options for COVID-19. The evolution of SARS-CoV-2 virus has led to the emergence of virus variants with reduced sensitivity to some antibody-based therapies. The development of potent antibodies with a broad spectrum of neutralizing activity is urgently needed. Here we isolated a panel of single-domain antibodies that specifically bind to the receptor-binding domain of SARS-CoV-2 S glycoprotein. Three of the selected antibodies exhibiting most robust neutralization potency were used to generate dimeric molecules. We observed that these modifications resulted in up to a 200-fold increase in neutralizing activity. The most potent heterodimeric molecule efficiently neutralized each of SARS-CoV-2 variant of concern, including Alpha, Beta, Gamma, Delta and Omicron variants. This heterodimeric molecule could be a promising drug candidate for a treatment for COVID-19 caused by virus variants of concern. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Favorskaya, Shcheblyakov, Esmagambetov, Dolzhikova, Alekseeva, Korobkova, Voronina, Ryabova, Derkaev, Kovyrshina, Iliukhina, Botikov, Voronina, Egorova, Zubkova, Ryzhova, Aksenova, Kunda, Logunov, Naroditsky and Gintsburg.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu